Health Payer Intelligence October 12, 2023
Victoria Bailey

Drug companies and pharmaceutical groups are suing HHS, arguing that the Medicare drug price negotiation rule violates constitutional amendments.

The Medicare drug price negotiation provisions in the Inflation Reduction Act hold promising spending reductions for beneficiaries, but drug companies are not backing down without a fight.

In August 2023, HHS announced the first ten drugs that will be available for Medicare price negotiation starting in 2026. The Department will undergo negotiations with drug companies in 2023 and 2024 for the following drugs: Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and Fiasp and NovoLog drugs.

The drugs treat various conditions, such as blood clots, diabetes, chronic kidney disease, heart failure, rheumatoid arthritis, and blood cancers. Between June 2022 and...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, CMS, Govt Agencies, HHS, Insurance, Medicare, Pharma, Pharma / Biotech
109 hospitals receiving new Medicare-backed residency slots
Senators urge Congress to avert Medicare physician pay cut
Podcast: Medicare Shared Savings Program Mints $2B Win for Value-Based Care w/ Frank McStay
Medicare Part D in 2025: A First Look at Prescription Drug Plan Availability, Premiums, and Cost Sharing
Dr. Oz, RFK Jr. on Medicare, Medicaid: 10 notes

Share This Article